JSKN021 / Alphamab - LARVOL DELTA

JSKN021:…Expected Milestones in 2026 (from Q2 2026) (Alphamab Press Release) - "Dose escalation for JSKN021 will be completed."

Trial status • Solid Tumor

Alphamab Oncology…is pleased to announce that the Investigational New Drug (the 'IND') application for JSKN021…has been officially accepted by the Center for Drug Evaluation (the 'CDE') of the National Medical Products Administration of China (the 'NMPA') (HKEXnews) - "The Company plans to initiate a phase I clinical study of JSKN021 for the treatment of advanced malignant solid tumors, aiming to evaluate its safety, tolerability, pharmacokinetics and antitumor activity in such patient population and to determine the maximum tolerated dose and/or recommended Phase II dose."

New P1 trial • Solid Tumor

Early-stage R&D:…Expected Milestones in 2025 (PRNewswire-Asia) - "(i) JSKN027: File an IND application with the CDE; (ii) JSKN021: File an application for a phase I clinical study in Australia."

New trial • Solid Tumor

JSKN021, an innovative site-specific dual-payload bispecific antibody drug conjugate targeting EGFR and HER3 exhibits potent preclinical activities (AACR 2025) - "The preclinical studies suggest JSKN021, as a dual-payload EGFR/HER3 bispecific ADC, might be a promising novel antitumor therapeutic agent."

Preclinical • Oncology • EGFR • ERBB3